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Background: Chronic lymphocytic leukemia (CLL) is the rarest adult leukemia in Japan, whereas it is the most
common leukemia in the Western world. Recent studies from the United States and Germany suggest a possible
etiological association between Merkel cell polyomavirus (MCPyV) and CLL, although no data have been reported
from Eastern countries. To increase the volume of relevant data, this study investigated the prevalence and DNA
loads of MCPyV and human polyomavirus 9 (HPyV9), another lymphotropic polyomavirus, in Japanese CLL cases.
Findings: We found that 9/27 CLL cases (33.3 %) were positive for MCPyV using quantitative real-time polymerase
chain reaction analysis. The viral DNA loads ranged from 0.000017 to 0.0012 copies per cell. All cases were negative
for HPyV9. One MCPyV-positive CLL case was evaluated by mutational analysis of the large T (LT) gene, which
indicated the presence of wild-type MCPyV without a nucleotide deletion. DNA sequence analysis of the entire
small T (ST) gene and the partial LT gene revealed that a Japanese MCPyV isolate, designated CLL-JK, had two
nucleotide gaps when compared with the reference sequence of the North American isolate MCC350.
Conclusions: This study provides the first evidence that MCPyV is present in a subset of Japanese CLL cases with
low viral DNA loads. MCPyV and HPyV9 are unlikely to contribute directly to the development of CLL in the majority
of Japanese cases. MCPyV isolated from the Japanese CLL cases may constitute an Asian group and its
pathogenicity needs to be clarified in future studies.
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Chronic lymphocytic leukemia (CLL) is the most common
form of adult leukemia in the Western countries, where its
frequency is ca. 3–8 new cases per 100,000 persons per
year [1-3]. However, CLL is very rare in far Eastern coun-
tries. The incidence of CLL in Japan is 0.48 per 100,000
persons per year, although the proportion of T-CLL is rela-
tively high [4]. It has been suggested that genetic predis-
position is a causal factor in CLL, but other largely
unknown etiological factors may contribute to the geo-
graphical difference in the CLL frequency. Infectious
agents may be correlated directly or indirectly with the
pathogenicity of CLL, including viral infections.* Correspondence: daibatam@kochi-u.ac.jp
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reproduction in any medium, provided the orPolyomaviruses are nonenveloped icosahedral viruses
with a circular double-stranded DNA genome that
encodes certain oncoproteins and they are putative onco-
genic viruses [5]. Currently, nine human polyomaviruses
are known but their precise roles in carcinogenesis remain
poorly understood [6]. The fifth polyomavirus, Merkel cell
polyomavirus (MCPyV), was reported in 2008 by Feng
et al. [7]. It was detected in approximately 80 % of Merkel
cell carcinomas (MCCs), which is an aggressive neuroen-
docrine skin carcinoma. Human polyomavirus 9 (HPyV9)
was identified recently in the serum of kidney transplant
patients who were receiving immunosuppressive treatment
[8]. The presence of the HPyV9 genome in particular dis-
eases has not been clarified. MCPyV and HPyV9, with a
close phylogenetic relationship to the African green
monkey-derived lymphotropic polyomavirus, have the po-
tential to infect lymphoid cells [8,9].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has a role in etiopathogenesis is currently an important
issue [10]. The possible association of MCPyV with various
lymphoid malignancies was first demonstrated by US
researchers, but they did not find a significant association
between CLL and MCPyV [11,12]. However, Canadian and
German studies detected MCPyV-positive CLL cases and
suggested the possible involvement of MCPyV in a subset
of CLLs [13-15]. More recently, another US group
reported MCPyV-positive CLLs with very low MCPyV
copy numbers [16]. Thus, all investigations of links be-
tween MCPyV and CLL have come from the Western
world, whereas the prevalence of MCPyV in CLL cases in
Eastern countries has not been investigated.
In this study, we aimed to determine the prevalence
and DNA loads of MCPyV and HPyV9 in Japanese CLL
cases, and we provide the first findings of a relationship
between CLL and new human polyomaviruses in the
Eastern world.
Methods
Patients and DNA preparation
We recruited 27 Japanese patients with CLL, including
25 B-CLLs and 2 T-CLLs (cases 3 and 17). The cohort
comprised 18 males and nine females with a median age
of 63 years at diagnosis (range 49–93). We also studied
peripheral blood samples from 18 healthy Japanese
donors with a median age of 48 years (range 27–55). A
serum fraction containing abundant leukemia cells was
separated using Ficoll–Conray density gradient and fro-
zen at −80°C until use. Total DNA was extracted using
the standard phenol–chloroform method. Approval was
obtained from the ethics committee for this study.
Quantitative real-time polymerase chain reaction (PCR)
Quantitative real-time PCR was conducted with 500 ng of
extracted DNA, according to the method of Bhatia et al.
[17] with some modifications. The primer and probe
sequences are shown in Table 1. The primers and probe
used for detecting the VP1 gene of HPyV9 were designed
based on the GenBank sequence NC015150. Standard
PCR was conducted using the same primers and the PCR
product was cloned into the pMD20-T vector (TaKaRa,
Shiga, Japan). We prepared six-fold serial dilutions using
10 ng of the cloned plasmid DNA to generate a standard
curve and we calculated the copy number in each sample.
The viral DNA load was defined as the viral DNA copies
per RNase P gene copy, which represented the copy num-
ber per cell.
PCR and DNA sequence analysis
MCPyV-positive samples identified by real-time PCR
amplification were subjected to mutational analysis of
the large T (LT) gene using standard PCR, as reported byPantulu et al. [14]. The primers shown in Table 1 yielded
a 355-bp PCR product representing wild-type MCPyV,
while the 120-bp product represented mutated MCPyV
with a nucleotide deletion [14].
Nucleotide sequences at positions 183 to 1157 (based
on the GenBank sequence EU375803), including the en-
tire small T (ST) gene and the partial LT gene, were also
investigated by standard PCR for 35 cycles using two
overlapping primer sets (nucleotide 183 to 828 and nu-
cleotide 571 to 1157) (Table 1). We expected amplicons
of 646 bp and 587 bp with these PCR amplifications.
The PCR products were gel purified and directly
sequenced with a Big Dye Terminator Cycle Sequencing
Kit (Life Technologies, Tokyo, Japan) on a 3130 Genetic
Analyzer Instrument (Applied Biosystems, Tokyo, Japan).
The nucleotide sequences that we obtained were ana-
lyzed using the BioEdit program and deposited in Gen-
Bank under accession number AB709861. The DNA
sequence data were compared with reference sequences
of MCPyV isolates from the National Center for Biotech-
nology Information Entrez Nucleotide database
(MCC350, MCC339, MKL-1, TKS, and 16b) and from a
previous report (B.C.) [18].
Results and discussion
We found that 9/27 CLL cases (33.3 %) were positive for
MCPyV according to the real-time PCR analysis (Table 2).
Previous studies conducted in Canada, Germany, and the
USA detected MCPyV in 20.8 % (5/24), 27.1 % (19/70),
and 33.3 % (6/18) of CLL cases, respectively [13,14,16].
Thus, our MCPyV detection rate was similar to that
reported from Western countries. The DNA loads of the
nine MCPyV-positive cases ranged from 0.000017 to
0.0012 copies per cell (Table 2), which was consistent with
previous data from North American CLL cases where viral
DNA loads were< 0.0004 [16]. Our real-time PCR analysis
showed that the copy numbers of nine MCPyV-positive
Japanese MCC controls ranged from 1.25 to 8.32 (data not
shown). Thus, the MCPyV-positive Japanese CLL cases
had 3–5 log lower copy numbers compared with the
MCPyV-positive Japanese MCCs. One of the 18 peripheral
blood samples from healthy Japanese donors was positive
for MCPyV with 0.00015 copies per cell (data not shown).
A two-tailed Fisher's exact test with a significant level of
P< 0.05 showed that the MCPyV detection rate in CLL
patients was significantly higher than that in healthy indi-
viduals (P=0.034). However, Shuda et al. [11] proposed
that samples with< 0.001 copies per cell should be consid-
ered MCPyV-negative when determining the frequency of
MCPyV in lymphomas. Thus, all of our cases would be
negative for MCPyV, except case 19, if we applied their de-
tection limit. Recently, Pancaldi et al. [18] reported that
MCPyV was also detectable in the buffy coats of healthy
Italian blood donors whose viral DNA loads ranged from
Table 1 Primer sequences used in this study
Real-time PCR analysis
Target gene Forward (5′!3′) Reverse (5′! 3′) Probe (5′! 3′)
MCPyV ST GCAAAAAAACTGTCTGACGTGG CCACCAGTCAAAACTTTCCCA FAM-TATCAGTGCTTTATTCTTTGGTTTGGATTTCCTCCT-
TAMRA
HPyV9 VP1 TGCTGTTGATATTGTTGGAATTCA AACAACCCGTTTCCTTAGAGTTACA FAM-CTGGAGAGGCCTACCT-NFQ-MGB




Forward (5′!3′) Reverse (5′! 3′)
MCPyV LT (1867–2221) AGCCCCCTTACAAATTACTGCAAG* AGCATTTCTGTCCTGGTCATTTC*
MCPyV ST-LT (183–828) GCATATAGACAAGATGGATTTA† ATAACCTTTCTTTGATATTTTGC†
MCPyV ST-LT (571–1157) TTGTCTCGCCAGCATTGTAG† GGATCCAGAGGATGAGGTGGGTTC†
*Primers for mutational analysis.
†Primers for sequence analysis of the ST-LT genes.
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our CLL cases harbored only low-level viral loads, so this
study provided little support for a direct causal role of
MCPyV in the majority of Japanese CLL cases.
We tested the nine MCPyV-positive cases to determine
the presence of truncating mutations of the LT gene,
which have been reported previously [14]. However, LT
sequences were not detectable in all samples by standard
PCR, possibly because of the low viral DNA loads. The
355-bp amplicon was only detected in case 21 without
the nucleotide deletion, indicating a wild-type MCPyV
infection in this case. Pantulu et al. [14] detected the
mutated LT gene in 6/19 MCPyV-positive German CLLTable 2 DNA loads of MCPyV and HPyV9 detected by
quantitative real-time PCR
Case Viral DNA load
(copies per cell)
Case Viral DNA load
(copies per cell)
MCPyV HPyV9 MCPyV HPyV9
1 - - 15 - -
2 - - 16 - -
3 - - 17 - -
4 0.000034 - 18 0.00041 -
5 - - 19 0.0012 -
6 - - 20 0.00041 -
7 - - 21 0.000039 -
8 - - 22 0.000051 -
9 - - 23 - -
10 - - 24 0.000017 -
11 - - 25 0.00061 -
12 - - 26 0.000027 -
13 - - 27 - -
14 - -patients, but it is uncertain whether such truncating LT
mutations are prevalent in Japanese CLL cases.
We also investigated the DNA sequences of the MCPyV
ST-LT genes at positions 183 to 1157. The 646-bp and
587-bp products were amplified in five cases, i.e., cases 18,
19, 21, 22, and 25. The sequencing results for the PCR
amplicons showed that their nucleotide sequences were
identical. The sequences found in our CLL cases, desig-
nated CLL-JK, shared two nucleotide gaps at positions 774
and 775 with sequences from another Japanese isolate,
TKS [GenBank: FJ464337] [19], and Asian isolate 16b
[HM011548] [9], when compared with the sequence of
North American isolate MCC350 [EU375803] (Figure 1).
Touzé et al. [20] reported that the nucleotide sequences of
French MCPyV isolates were different from the MCC350
isolate, but homologous to the Swedish isolate MKL-1
[FJ173815]. A recent study also showed that the nucleotide
sequence of the Italian isolate B.C. shared 100 % homology
with MKL-1 [18]. It is likely that the MCPyV strains circu-
lating in Europe are genetically conserved. Thus, the CLL-
JK isolate with nucleotide gaps, TKS, and 16b, may be clas-
sified with the Asian group, which is distinct from the
European and North American groups. It is notable that a
C to T substitution was common in the TKS and 16b iso-
lates at position 958 in the exon 2 region of the LT gene
(Figure 1), which resulted in an amino acid substitution of
His to Tyr. It is not known whether the genetic diversity of
the Asian group affects the pathogenicity of MCPyV.
We also aimed to determine whether the lymphotropic
polyomavirus HPyV9 was associated with CLL. We found
that no cases with CLL or healthy donors had amplifiable
HPyV9 DNA according to the highly sensitive real-time
PCR (Table 2). Our results appear to indicate that HPyV9
is not involved directly in the leukemogenesis of CLL.
In summary, this study provides the first evidence of
MCPyV DNA in a subset of Japanese CLL cases.
nt205 
MCC350   GTCCTAAATAGGAAAGAAAGAGAGGCTCTGTGCAAGCTTTTGGAGATTGCTCCTAATTGTTATGGCAACATCCCTCTGATGAAAGCTGCTTTCAAAAGAA
MCC339   ........C....................C...........A..........................................................
MKL-1    .............................C...........A..........................................................
TKS      .............................C...........A..........................................................
16b      .............................C...........A..........................................................
B.C.     ----------------------------------------------------------------------------------------------------
CLL-JK   .............................C...........A..........................................................
 nt305 
MCC350   GCTGCTTAAAGCATCACCCTGATAAAGGGGGAAATCCTGTTATAATGATGGAATTGAACACCCTTTGGAGCAAATTCCAGCAAAATATCCACAAGCTCAG
MCC339   ....................................................................................................
MKL-1    ....................................................................................................
TKS      ....................................................................................................
16b      ....................................................................................................
B.C.     ----------------------------------------------------------------------------------------------------
CLL-JK   ....................................................................................................
 nt405 
MCC350   AAGTGACTTCTCTATGTTTGATGAGGTTAGTACAAAATTTCCTTGGGAAGAATATGGAACTTTAAAGGATTATATGCAAAGTGGATATAATGCTAGATTT
MCC339   ...........................C........................................................................
MKL-1    ...........................C........................................................................
TKS      ...........................C........................................................................
16b      ...........................C........................................................................
B.C.     ----------------------------------------------------------------------------------------------------
CLL-JK   ...........................C........................................................................
 nt505 
MCC350   TGCAGAGGTCCTGGGTGCATGCTTAAGCAACTTAGAGATTCTAAGTGCGCTTGTATTAGCTGTAAGTTGTCTCGCCAGCATTGTAGTCTAAAAACTTTAA
MCC339   ....................................................................................................
MKL-1    ....................................................................................................
TKS      ....................................................................................................
16b      ....................................................................................................
B.C.     ------------------------------------------------------------------..................................
CLL-JK   ....................................................................................................
 nt605 
MCC350   AGCAAAAAAACTGTCTGACGTGGGGAGAGTGTTTTTGCTATCAGTGCTTTATTCTTTGGTTTGGATTTCCTCCTACTTGGGAAAGTTTTGACTGGTGGCA
MCC339   ....................................................................................................
MKL-1    ....................................................................................................
TKS      ....................................................................................................
16b      ...........................................................................................T........
B.C.     ....................................................................................................
CLL-JK   ....................................................................................................
 nt705 
MCC350   AAAAACTTTAGAAGAAACTGACTACTGCTTACTGCATCTGCACCTTTTCTAGACTCCTACTTCCTTCCTCTGTAAGTATTAGATATGGAAAAGTCTATAA
MCC339   ....................................................................................................
MKL-1    ....................................................................................................
TKS      .....................................................................--.............................
16b      .....................................................................--.............................
B.C.     ....................................................................................................
CLL-JK   .....................................................................--.............................
 nt805 
MCC350   GGCAAAATATCAAAGAAAGGTTATTTATGACAGATTTTGTGTACTTTCCCATCTAGGTTGACGAGGCCCCTATATATGGGACCACTAAATTCAAAGAATG
MCC339   ......................................C.............................................................
MKL-1    ......................................C.............................................................
TKS      ......................................C.............................................................
16b      ......................................C.............................................................
B.C.     ......................................C.....................................------------------------
CLL-JK   ......................................C.............................................................
 nt905 
MCC350   GTGGAGATCAGGAGGATTCAGCTTCGGGAAGGCATACGAATATGGGCCCAATCCACACGGGGCCAACTCAAGATCCAGAAAGCCTTCCTCCAATGCATCC
MCC339   .............................................................A......................................
MKL-1    .............................................................A......................................
TKS      .......................................................T.....A......................................
16b      .......................................................T.....A......................................
B.C.     ----------------------------------------------------------------------------------------------------
CLL-JK   .............................................................A......................................
 nt1005 
MCC350   AGGGGAGCCCCCAGTGGAAGCTCACCACCCCACAGCCAGAGCTCTTCCTCTGGGTATGGGTCCTTCTCAGCGTCCCAGGCTTCAGACTCCCAGTCCAGAG
MCC339   ....................................................................................................
MKL-1    ....................................................................................................
TKS      ....................................................................................................
16b      ....................................................................................................
B.C.     ----------------------------------------------------------------------------------------------------
CLL-JK   ....................................................................................................
 nt1105 
MCC350   GACCCGATATACCTCCCGAACACCATGAG  
MCC339   .............................  
MKL-1    .............................  
TKS      .............................  
16b      .............................  
B.C.     ----------------------------- 
CLL-JK   .............................  
Figure 1 Nucleotide comparison of the MCPyV isolate, designated CLL-JK, with the reference isolates. Regions coding the ST gene are
represented as gray boxes. The gray boxes with black lines and white boxes with gray lines correspond to exon 1 and exon 2 of the LT gene,
respectively. Nucleotide substitutions are shown in bold and compared with the nucleotide sequence of MCC350.
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http://www.jhoonline.org/content/5/1/25Mutational analysis of the MCPyV LT gene was not fully
evaluated because of low viral DNA levels, but one
MCPyV-positive CLL case had wild-type MCPyV. These
findings suggest that MCPyV is unlikely to have a direct
causal role in the majority of Japanese CLL cases. DNA se-
quence analysis revealed that the MCPyV isolates found in
our CLL patients constituted an Asian group with two nu-
cleotide gaps. We also showed that HPyV9 was not
present in Japanese CLL cases. Further worldwide epi-
demiological and virological studies are required to deter-
mine the pathogenetic relevance of human polyomaviruses
in CLL.
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